Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE Insider Trading

<< Previous

Bullboard Posts

Next >>

Post by davgroon Jul 15, 2022 1:56pm

229 Views

Post# 34827546

ATE Insider Trading

Now that I have the Dumpster back on IGNORE we can engage in some relevant ATE discussions.

There has been a lot of discussion recently about Insider Trades. I grabbed a good chart that outlines ATE insider trades for the last 2 years. Looking only at dollar values the insider trades have been insignificant other than a $300K sell in Q1 2021. I personally see nothing positive or negative in recent ATE insider trades, or lack thereof. Moving forward my focus is entirely on the science and I am optimistic that "long-term" my investment in ATE will pay off.

User image